LPTX - LEAP THERAPEUTICS, INC.
IEX Last Trade
2.94
0.010 0.340%
Share volume: 527
Last Updated: Fri 27 Dec 2024 08:29:59 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$2.93
0.01
0.34%
Fundamental analysis
29%
Profitability
43%
Dept financing
15%
Liquidity
50%
Performance
15%
Performance
5 Days
3.11%
1 Month
2.05%
3 Months
10.37%
6 Months
68.36%
1 Year
-32.73%
2 Year
-31.19%
Key data
Stock price
$2.94
DAY RANGE
$2.91 - $2.96
52 WEEK RANGE
$1.79 - $5.00
52 WEEK CHANGE
-$28.11
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO: Doug E. Onsi
Region: US
Website: leaptx.com
Employees: 40
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: leaptx.com
Employees: 40
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Leap Therapeutics, Inc. acquires and develops therapies for the treatment of cancer. DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers.
Recent news